Natalie E. West M.D., M.H.S.

Assistant Professor Of Medicine

Natalie West is an Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the Johns Hopkins Hospital. Dr. West graduated from University of Florida with a degree in Finance in 1999, and then graduated from the University of South Florida School of Medicine in 2004. She completed Internal Medicine Residency at Vanderbilt University in 2007, and was the Hugh Jackson Morgan Chief Resident from 2007-08. Dr. West then completed Pulmonary and Critical Care Medicine Fellowship at Johns Hopkins University from 2008-12, and remained on faculty thereafter. Dr. West's area of clinical and research expertise is cystic fibrosis. She has received a Masters in Health Sciences degree in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health, through the full-time Graduate Training Program in Clinical Investigation (GTPCI). She currently has the Harry Shwachman Cystic Fibrosis Clinical Investigator Award evaluating biomarkers during periods of pulmonary exacerbations, which are repeated events in the lives of individuals with cystic fibrosis. Additionally, Dr. West is one of the national investigators that has been integral in the design of a large trial coordinated through the Cystic Fibrosis Therapeutic Development Network, which is examining treatment of pulmonary exacerbations (Standardized Treatment of Pulmonary Exacerbations II (STOP2)). She is the site PI for Johns Hopkins for this trial. Cystic fibrosis research her area of expertise, and she has 10 years' successful collaboration with all the members of the cystic fibrosis team at Johns Hopkins. It is her career goal to conduct multi-center robust clinical trials in cystic fibrosis research. Dr. Wests has spoken nationally (North American Cystic Fibrosis Conference (NACFC)) and internationally (European Cystic Fibrosis Conference) on the results of the STOP pilot study, which was completed before initiation of the STOP2 trial. Dr. West will be speaking in a Symposium at this year's NACFC on pulmonary exacerbations.


Appearances